All In Biotech

Drug Trial Radar · NCT01189760

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Last checked: Nov 20, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 917 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

917

Actual

Start

Sep 1, 2010

Primary completion

Mar 1, 2011

Study completion Sep 1, 2011

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)

Conditions

  • Facial Rhytides
  • Crow's Feet Lines
  • Glabellar Lines

Interventions

  • onabotulinumtoxinA 24 UBiological

    24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.

  • onabotulinumtoxinA 44 UBiological

    44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart

  • normal salineDrug

    Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum SmileTime frame: Baseline, Day 30

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Newport Beach, California

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Antibes, France

  • Site not named

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.